NBEO Part II Treatment and Management of Ocular Disease (TMOD) Practice Test

Macular edema can be triggered by systemic medications that affect retinal vascular permeability or retinal cells. Several drugs have been linked to this complication, so the safest conclusion is that all of these listed medications can be associated with macular edema.

Glitazones (thiazolidinediones) used for diabetes have been reported to cause macular edema, sometimes presenting in patients with underlying diabetic retinopathy. The edema may resolve after stopping the medication, underscoring the drug-related nature of the finding.

Fingolimod (Gilenya), prescribed for multiple sclerosis, is a well-known inducer of cystoid macular edema. The risk is highest in the first weeks to months of therapy, so clinicians monitor vision and OCT during this period and may adjust treatment if edema develops.

Retrovir (AZT) has also been described in case reports as associated with macular edema, though less commonly than the others. The mechanism isn’t completely understood but may involve vascular or cellular toxicity affecting the retina.

Because edema can arise from different pathways yet present similarly on exam and imaging, recognizing that these diverse drugs can cause macular edema helps guide timely evaluation and management. If a patient on any of these medications develops visual symptoms or noticeable edema on exam, coordinated care to reassess the medication choice and treat the edema as appropriate is warranted.